期刊文献+

我院抗肿瘤及辅助治疗药物不良反应164例分析 被引量:13

An Analysis of 164 Cases of Anticancer and Supplementary Drugs Adverse Reactions
下载PDF
导出
摘要 目的对我院肿瘤内科不良反应(ADR)的发生情况及特点进行分析,为临床合理用药提供参考。方法采用回顾性分类统计,对164例报告涉及的患者年龄、性别、给药途径药物类别以及临床表现进行分析。结果 164例ADR中男性76例,女性88例;40岁以上154例;细胞毒类药物的发生率居首,占77.9%;ADR的临床表现以消化系统反应为主,其次为骨髓抑制。结论开展ADR监测工作是医务人员,特别是临床药师的重要任务,加强ADR监测,保障患者用药安全。 Objective To provide reference for clinical rational drug use,the tumor patients's adverse drug reacton(ADR) occurrence and characteristics in our hospital were analyzed.Methods In this paper,164 cases of patients with anti-tumor drug adverse reaction reports were retrospective analyzed on the age,sex,administration way,drug classes and clinical manifestations.Results The results showed that adverse drug reacton mainly happened in the 40 years and old tumor patients.Cytotoxic drugs take the highest incidence.The clinical manifestations of adverse drug reacton in gastrointestinal reaction is given priority,followed by bone marrow inhibition.Conclusion Adverse drug reacton monitoring and reporting work which ensure patients safely use their drugs is the medical staff,especially the clinical pharmacists important task.
出处 《中国药物警戒》 2012年第3期184-186,共3页 Chinese Journal of Pharmacovigilance
关键词 抗肿瘤药物 不良反应 合理用药 antitumor drugs adverse drug reacton rational drug use
  • 相关文献

参考文献5

二级参考文献19

共引文献85

同被引文献115

  • 1任晓辉,黄莹.我院2009—2011年抗肿瘤药物使用情况分析[J].兵团医学,2013(2):59-62. 被引量:1
  • 2刘贤铭.抗肿瘤药物不良反应及其防治[J].中国药事,2005,19(10):636-638. 被引量:12
  • 3宁华,刘颖,张艳华,姜洋.抗肿瘤药的常见不良反应及防治[J].中国医院用药评价与分析,2007,7(1):76-79. 被引量:33
  • 4张之南.血液病学[M].北京:人民卫生出版社,2003.1101-1106.
  • 5Nebeker JR,Barach P,Samore MH. Clarifying adverse drug events:a clinician's guide to terminology,documen- tation,and reporting [J]. Ann Intern Med, 2004,140 (10):795-801.
  • 6Leguy-Seguin V,Jolimoy G,Coudert B. Diagnostic and predictive value of skin testing in platinum salt hyper- sensitivity [J]. J Allergy Clin Immunol,2007,119 (3) : 726-730.
  • 7Castells MC ,Tennant NM, Sloane DE. Hypersensitivity re- actions to chemotherapy:outcomes and safety of rapid de- sensitization in 413 cases[J]. J Allergy Clin Immunol, 2008,122(3) :574-580.
  • 8Waddell T, Gollins S, Soe W, et al. Phase II study of short- course capecitabine plus oxaliplatin (XELOX) followed by ma- intenance capecitabine in advanced colorectal cancer: XelQuali study[J]. Cancer Chemother Pharmacol, 2011,67 ( 5 ) : 1111- 1117.
  • 9Lubner SJ, Loconte NK, Holen KD, et al. phase II study of ox aliplatin, 5-fluorouracil, leucovorin, and high-dose eapecitabine in patients with metastatic colorectal cancer[J]. Clin Colorectal Cancer,2010,9(3) : 157-161.
  • 10Ramani VS, Sun Myint A, Montazeri A, et al. Preoperative chemoradiotherapy for rectal cancer: a comparison between in- travenous 5-fluorouracil and oral capecitabine [J]. Colorectal Dis,2010,12(Suppl 2):37-46.

引证文献13

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部